Torsades de pointes after administration of low-dose aripiprazole

Annals of Pharmacotherapy

Volumn 47, Issue 2, 2013, Pages

  Nelson, Sarah ^a   Leung, Jonathan G ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; FAMOTIDINE; MAGNESIUM SULFATE;

ADULT; ARTICLE; BEDTIME DOSAGE; CASE REPORT; CEREBROVASCULAR ACCIDENT; DELIRIUM; DIABETES MELLITUS; DIARRHEA; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FEVER; HEART ARREST; HEART CATHETERIZATION; HUMAN; HYPERTENSION; LABORATORY TEST; LOW DRUG DOSE; MALE; MENTAL DISEASE; PRIORITY JOURNAL; QT PROLONGATION; RESUSCITATION; SCHIZOPHRENIA; TORSADE DES POINTES;

EID: 84873947559     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1R387     Document Type: Article

References (46)

1. Jacobi J, Fraser GL, Coursin DB, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med 2002;30:119-41.
2. Skrobik YK, Bergeron N, Dumont M, Gottfried SB. Olanzapine vs haloperidol: treating delirium in a critical care setting. Intensive Care Med 2004;30:444-9. doi: 10.1007/s00134-003-2117-0
3. Devlin JW, Roberts RJ, Fong JJ, et al. Efficacy and safety of quetiapine in critically ill patients with delirium: a prospective, multicenter, randomized, double-blind, placebo-controlled pilot study. Crit Care Med 2010; 38:419-27. doi: 10.1097/CCM.0b013e3181b9e302
4. Girard TD, Pandharipande PP, Carson SS, et al. Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: the MIND randomized, placebo-controlled trial. Crit Care Med 2010;38:428-37. doi: 10.1097/CCM.0b013e3181c5871
5. Boettger S, Friedlander M, Breitbart W, Passik S. Aripiprazole and haloperidol in the treatment of delirium. Aust N Z J Psychiatry 2011;45: 477-82. doi: 10.3109/00048674.2011.543411
6. Boettger S, Breitbart W. An open trial of aripiprazole for the treatment of delirium in hospitalized cancer patients. Palliat Support Care 2011;9:351-7. doi: 10.1017/S1478951511000368
7. Straker DA, Shapiro PA, Muskin PR. Aripiprazole in the treatment of delirium. Psychosomatics 2006;47:385-91.
8. Alao AO, Moskowitz L. Aripiprazole and delirium. Ann Clin Psychiatry 2006;18:267-9. doi: 10.1080/10401230600948506
9. Alao AO, Soderberg M, Pohl EL, Koss M. Aripiprazole in the treatment of delirium. Int J Psychiatry Med 2005;35:429-33.
10. Han CS, Kim YK. A double-blind trial of risperidone and haloperidol for the treatment of delirium. Psychosomatics 2004;45:297-301.
11. Miyaji S, Yamamoto K, Hoshino S, Yamamoto H, Sakai Y, Miyaoka H. Comparison of the risk of adverse events between risperidone and haloperidol in delirium patients. Psychiatry Clin Neurosci 2007;61:275-82. doi:10.1111/j.1440-1819.2001.01655.x
12. Kim SW, Yoo JA, Lee SY, et al. Risperidone versus olanzapine for the treatment of delirium. Hum Psychopharmacol 2010;25:298-302. doi: 10.1002/hup.1117
13. Mittal D, Jimerson MA, Neely EP, et al. Risperidone in the treatment of delirium: resulting from a prospective open-label trial. J Clin Psychiatry 2004;65:662-7.
14. Liu CY, Juang YY, Liang HY, Lin NC, Yeh EK. Efficacy of risperidone in treating the hyperactive symptoms of delirium. Int Clin Psychopharmacol 2004;19:165-8.
15. Grover S, Kumar V, Chakrabarti S. Comparative efficacy study of haloperidol, olanzapine, and risperidone in delirium. J Psychosom Res 2011;71:277-81.
16. Horikawa N, Yamazaki T, Miyamoto K, et al. Treatment for delirium with risperidone: results of a prospective open trial with 10 patients. Gen Hosp Psychiatry 2003;25:289-92.
17. Parellada E, Baeza I, de Pablo J, Martinez G. Risperidone in the treatment of a patient with delirium. J Clin Psychiatry 2004;65:348-53.
18. Lacasse H, Perreault MM, Williamson DR. Systematic review of antipsychotics for the treatment of hospital-associated delirium in medically or surgically ill patients. Ann Pharmacother 2006;40:1966-73.
19. 2 atypical antipsychotics. Am J Psychiatry 2010;162:1984-5.
20. Stahl SM. "Hit-and-run" actions at dopamine receptors, part 1: mechanism of action of atypical antipsychotics. J Clin Psychiatry 2001;19:165-8.
21. Li EC, Esterly JS, Pohl S, Scott SD, McBride BF. Drug-induced QT-interval prolongation: considerations for clinicians. Pharmacotherapy 2010;30:684-701.
22. Gupta A, Lawrence AT, Krishnan K, Kavinsky CJ, Trohman RG. Current concepts in the mechanisms and management of drug-induced QT prolongation and torsades de pointes. Am Heart J 2007;153:891-9.
23. Falagas ME, Rafailidis PI, Rosmarakis ES. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents 2007;29:374-9.
24. Veiweg WV, Wood MA, Fernandez A, Beatty-Brooks M, Hasnain M, Pangurangi AK. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging 2009;26:997-1012.
25. Meyer-Massetti C, Cheng CM, Sharpe BA, Meier CR, Guglielmo BJ. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? J Hosp Med 2010;5:E8-16. doi: 10.1002/jhm.691
26. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004;24:62-9.
27. Psychopharmacological Drugs Advisory Committee. 19 July, 2000. Briefing document for Zeldox capsules (ziprasidone hydrochloride). www.fda.gov/ohrms/dockets/ac/00/backgrd/3619b1.htm (accessed 2012 Jun 1).
28. Product information. Seroquel (quetiapine). Wilmington, DE: AstraZeneca, July 2011.
29. Tan HH, Hoppe J, Heard K. A systematic review of cardiovascular effects after atypical antipsychotic medication overdose. Am J Emerg Med 2009;27:607-16. doi: 10.1016/j.ajem.2008.04.020
30. Lo B, Pizon A. Delayed presentation of an aripiprazole overdose (letter). Clin Toxicol (Phila) 2008;46:348-9. doi: 10.1080/15563650701704859
31. Suzuki Y, Orno S, Fukui N, et al. Dose-dependent increase in the QTc interval in aripiprazole treatment after risperidone (letter). Prog Neuropsychopharmacol Biol Psychiatry 2011;35:643-4. doi: 10.1016/j.pnpbp.2010.10.024
32. Leo R, Razzini C, Di Lorenzo G, et al. Asymptomatic QTc prolongation during coadministration of aripiprazole and haloperidol (letter). J Clin Psychiatry 2008;62:327-8.
33. LoVecchio F, Watts D, Winchell J. One-year experience with aripiprazole exposures (letter). Am J Emerg Med 2005;23:585-6.
34. Carstairs SD, Williams SR. Overdose of aripiprazole, a new type of antipsychotic. J Emerg Med 2005;28:311-3. doi: 10.1016/j.jemergmed.2004.09.013
35. Gulisano M, Calì PV, Cavanna AE, Eddy C, Rickards H, Rizzo R. Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome. Neurol Sci 2011;32:1213-7. doi: 10.1007/s10072-011-0678-1
36. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-36.
37. Berman RM, Marcus RN, Swanink R, et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2007;68:843-53.
38. Tran-Johnson TK, Sack DA, Marcus RN, Auby P, McQuade RD, Oren DA. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2007;68:111-9.
39. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
40. Pandharipande P, Cotton BA, Shintani A, et al. Motoric subtypes of delirium in mechanically ventilated surgical and trauma intensive care unit patients. Intensive Care Med 2007;33:1726-31.
41. Farah A. Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry 2005;7:268-74.
42. Product information. Abilify (aripiprazole). Princeton, NJ: Bristol-Meyers Squibb, February 2012.
43. Muzyk AJ, Rivelli SK, Gagliardi JP, Revollo JY, Jiang W. A retrospective study exploring the effects of intramuscular aripiprazole on QTc change in agitated medically ill patients (letter). J Clin Psychopharmacol 2011;31:532-4.
44. Endo T, Katoh T, Kiuchi K, Katsuta Y, Shimizu S, Takano T. Famotidine and acquired long QT syndrome. Am J Med 2000;108:438-9.
45. Lee KW, Kayser SR, Hongo RH, Tseng ZH, Scheinman. Famotidine and long QT syndrome. Am J Cardiol 2004;93:1325-7.
46. Nakamura Y, Takahara A, Sugiyama A. Famotidine neither affects action potential parameters nor inhibits ether-a-go-go-related gene (hERG) K+ current. J Toxicol Sci 2009;34:563-7.